Therefore, we suggest that the changes in the effects of GCGR and GLP-1R induced by metabolic stress should also be considered when designing GCGR- and GLP-1R-combined agonists for the treatment of diabetes. The gene discussed is GLP1R; the disease is diabetes mellitus.